TRIP

Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants

Cochrane Database of Systematic Reviews, 2000

Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants
Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration.
Not enough evidence to show the effectiveness of superoxide dismutase in preventing chronic lung disease in premature babies
Chronic lung disease (CLD) is a common problem in preterm babies who are mechanically ventilated (machine assisted breathing).
Superoxide dismutase is an enzyme normally present in the body to provide a defence against free radicals but preterm infants do not have a sufficient supply to provide natural resistance.
Free oxygen radicals have been implicated in the pathogenesis of chronic lung disease in preterm infants.
Superoxide dismutase is a naturally occurring enzyme which provides a defence against such oxidant injury.
Exogenously administered superoxide dismutase has been tested in clinical trials to prevent chronic lung disease in preterm infants.
To determine if exogenously administered superoxide dismutase is efficacious in the prevention of chronic lung disease in preterm infants who are mechanically ventilated, and efficacious in decreasing the following outcomes: bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, patent ductus arteriosus and mortality.
We searched Medline (1966 - 2000) and the Cochrane Controlled Trials Register (CCTR) using the following keywords: {bronchopulmonary dysplasia OR chronic lung disease} AND superoxide dismutase, limited to human studies in newborn infants (infant, newborn).